Skip to Content

CRO Selection & Qualification

How we help with CRO Selection & Qualification

The process of selecting and qualifying vendors for clinical trials is cumbersome and expensive. Halloran routinely provides qualifying and selecting the right vendor and negotiating optimal terms of the engagement which are critical to the timely completion of a high-quality study.

Our process starts with a narrow pool of candidate CROs or vendors who meet the highest-level performance criteria, provide uniform specifications to facilitate apples-to-apples comparisons, and critically review budgets, experience, data solutions, technology infrastructure, and other factors qualitatively and quantitatively. We assist our clients in budget and scope negotiations that help them avoid future change orders or surprises and incorporate risk-sharing incentives and penalties wherever possible.

We utilize our team’s extensive industry knowledge and experience to ensure an objective evaluation that takes into consideration any mitigating risks you may encounter to land at an optimal project outcome.

RELATED INSIGHTS

  • Read our latest Case StudyClinical Trial Rescue: Leadership Approach to Propel Clinical Development Situation A rare disease biotechnology company’s gene therapy clinical trial was put on hold, and the company found itself with a poor performing Clinical Trial Leader. Rudderless, and without a clear clinical operations strategy, they needed an experienced leader to navigate the […]

  • Many product developers are propelled by the goal of delivering life-saving treatments as quickly and as safely as possible to patients who are left with no other options. With oncology development, the standard 3+3 dose escalation in study design in first-in-human (FIH) clinical trials is still the standard, however, we should consider alternative Phase 1 […]

  • Read our latest Case Study Clinical Trial Leadership: Enhancing Efficiencies and Reducing Risk Situation A small biotech developing an innovative therapy needed to retain a clinical trial leader as they were launching their trial at multiple sites. The company experienced two cycles of leadership turnover, resulting in lagging strategy and operations. They needed to immediately […]